VIDA is a clinical imaging intelligence company that is accelerating the development of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, VIDA’s solution is helping biopharma sponsors save millions in drug development costs. | VIDA Content OS is the secure, cloud-native MAM platform trusted and used by major media and entertainment companies to store, archive, manage and distribute their high value long and short form content. It simplifies and streamlines their content operations and content supply processes, enabling better collaborations between internal teams and external stakeholders and accelerating the speed of content delivery. Visit us to discover why VIDA Content OS has been described by customers as ‘a game changer’, ‘indispensable’, and ‘significant breakthrough’. | VIDA is the secure, cloud-native MAM platform trusted and used by major media and entertainment companies to store, archive, manage and distribute their high-value long and short form content. It simplifies and streamlines their content operations and content supply processes, enabling better collaborations between internal teams and external stakeholders and accelerating the speed of content delivery. Visit us to discover why VIDA has been described by customers as ‘a game changer’, ‘indispensable’, and ‘significant breakthrough’. Powered by agentic AI, Media Factory orchestrates workflows that enrich, organise and route your content, all with less effort from your teams. | VIDA is the modern, cloud-based Media Asset Management (MAM) platform designed to help media organizations securely store, manage and distribute their content from one central platform. Used by broadcasters, streaming platforms, production companies and content creators worldwide, VIDA replaces legacy, on-premise MAM systems and fragmented cloud and local storage options with a modern, secure and scalable solution. Today’s Christian broadcasters, ministries and content teams are producing more content than ever before: television programs, movies, podcasts, sermons, promotional materials and social media content, all needing to be delivered securely and efficiently to affiliates, partners, platforms and audiences worldwide. Many organizations are still relying on legacy, on-premise systems or fragmented cloud storage that can slow teams down and create unnecessary risk. At the NRB Convention, we welcome the opportunity to speak with you about your current asset storage and content distribution challenges. We will share practical examples of how other broadcasters and media organizations use VIDA as a modern content operations solution to support growth, collaboration and mission impact while ensuring their teams are equipped to meet their organization’s objectives today and into the future.
Vertex Pharmaceuticals
Vertex invests in scientific innovation to create transformative medicines for people with serious diseases. Through cutting-edge science across multiple modalities, it has approved medicines that treat the underlying causes of multiple diseases and conditions and has a broad and deep clinical pipeline. Learn more at www.vrtx.com. | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy. | xxx | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for serious kidney diseases, including APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy and autosomal dominant polycystic kidney disease.
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
Thirona
Thirona provides advanced lung image analysis with artificial intelligence through expertise-based services for MedTech, pharmaceutical and CRO companies. Thirona’s lung quantification platform LungQ® consists of a comprehensive portfolio of robust high-performance algorithms trained on a wide range of disease-specific datasets, offering market-leading AI analytical capabilities, with consistent and reproducible results. Integrated in multiple certified clinical end-products, our software is used by clinicians in more than 600 hospitals worldwide.
Takeda
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our leadership in oncology extends more than 25 years and includes a range of therapies that have helped to transform the treatment landscape for previously underserved patient populations, in some cases shifting paradigms and becoming standard of care. We are building on our portfolio of approved medicines for hematologic cancers and solid tumors and advancing a cutting-edge pipeline focused on the power of innate immunity. We aim to introduce new classes of immunotherapies that can lead to deep, durable responses so that more patients can benefit from – and have access to – innovative medicines. | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. www.takeda.com | Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. | Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. www.takeda.com
SANOFI
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. | x